All In Biotech

Drug Trial Radar · NCT07217015

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Kymera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Conditions

  • Atopic Dermatitis

Interventions

  • KT-621Drug

    Oral drug

  • PlaceboOther

    Oral placebo matched to KT-621

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Eczema Area and Severity Index (EASI) scoreTime frame: From baseline through Week 16

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • Kymera Investigative Site

    Birmingham, Alabama

  • Kymera Investigative Site

    North Little Rock, Arkansas

  • Kymera Investigative Site

    Los Angeles, California

  • Kymera Investigative Site

    Los Angeles, California

  • Kymera Investigative Site

    Delray Beach, Florida

  • Kymera Investigative Site

    Jacksonville, Florida

  • Kymera Investigative Site

    Miami, Florida

  • Kymera Investigative Site

    Miami, Florida

  • Kymera Investigative Site

    Miramar, Florida

  • Kymera Investigative Site

    Normal, Illinois

  • Kymera Investigative Site

    Ann Arbor, Michigan

  • Kymera Investigative Site

    Detroit, Michigan

  • Kymera Investigative Site

    The Bronx, New York

  • Kymera Investigative Site

    Fargo, North Dakota

  • Kymera Investigative Site

    Portland, Oregon

  • Kymera Investigative Site

    Portland, Oregon

  • Kymera Investigative Site

    Philadelphia, Pennsylvania

  • Kymera Investigative Site

    San Antonio, Texas

  • Kymera Investigative Site

    San Antonio, Texas

  • Kymera Investigative Site

    Darlinghurst, New South Wales, Australia

  • Kymera Investigative Site

    Kogarah, New South Wales, Australia

  • Kymera Investigative Site

    Brisbane, Queensland, Australia

  • Kymera Investigative Site

    Woolloongabba, Queensland, Australia

  • Kymera Investigative Site

    Melbourne, Victoria, Australia

  • Kymera Investigative Site

    Calgary, Alberta, Canada

  • Kymera Investigative Site

    Edmonton, Alberta, Canada

  • Kymera Investigative Site

    Kelowna, British Columbia, Canada

  • Kymera Investigative Site

    Surrey, British Columbia, Canada

  • Kymera Investigative Site

    Markham, Ontario, Canada

  • Kymera Investigative Site

    Ottawa, Ontario, Canada

  • Kymera Investigative Site

    Richmond Hill, Ontario, Canada

  • Kymera Investigative Site

    Toronto, Ontario, Canada

  • Kymera Investigative Site

    Québec, Quebec, Canada

  • Kymera Investigative Site

    Pardubice, Czechia

  • Kymera Investigative Site

    Prague, Czechia

  • Kymera Investigative Site

    Bad Bentheim, Germany

  • Kymera Investigative Site

    Frankfurt, Germany

  • Kymera Investigative Site

    Mainz, Germany

  • Kymera Investigative Site

    Münster, Germany

  • Kymera Investigative Site

    München, Bavaria, Germany

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.